BLC
MCID: BLD134
MIFTS: 79

Bladder Cancer (BLC)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Nephrological diseases, Rare diseases

Aliases & Classifications for Bladder Cancer

MalaCards integrated aliases for Bladder Cancer:

Name: Bladder Cancer 57 12 20 43 73 36 29 54 42 15 37
Bladder Carcinoma 12 29 54 6 15 17
Urinary Bladder Cancer 12 73 29 6 15
Bladder Cancer, Somatic 57 13
Bladder Neoplasm 29 71
Cancer, Bladder 43 39
Bladder Tumor 43 17
Malignant Neoplasm of Urinary Bladder 71
Urothelial Carcinoma of the Bladder 73
Neoplasm of the Urinary Bladder 43
Cancer of the Urinary Bladder 43
Carcinoma of Urinary Bladder 12
Tumor of the Urinary Bladder 43
Malignant Bladder Neoplasm 43
Bladder Carcinoma Urinary 43
Urinary Bladder Carcinoma 43
Urinary Bladder Neoplasms 44
Urinary Bladder Neoplasm 43
Cancer, Urinary Bladder 43
Malignant Bladder Tumor 43
Neoplasm of the Bladder 43
Tumor of the Bladder 12
Carcinoma of Bladder 71
Bladder Tumors 54
Blc 73

Characteristics:

OMIM®:

57 (Updated 05-Mar-2021)
Inheritance:
somatic mutation


HPO:

31
bladder cancer:
Inheritance autosomal dominant inheritance somatic mutation


Classifications:



External Ids:

Disease Ontology 12 DOID:11054 DOID:4007
OMIM® 57 109800
KEGG 36 H00022
ICD9CM 34 188
MeSH 44 D001749
ICD10 32 C67 C67.9
MedGen 41 C0005684
SNOMED-CT via HPO 68 124975008 255109008 263681008
UMLS 71 C0005684 C0005695 C0699885

Summaries for Bladder Cancer

KEGG : 36 The urothelium covers the luminal surface of almost the entire urinary tract, extending from the renal pelvis, through the ureter and bladder, to the proximal urethra. The majority of urothelial carcinoma are bladder carcinomas, and urothelial carcinomas of the renal pelvis and ureter account for only approximately 7% of the total. Urothelial tumours arise and evolve through divergent phenotypic pathways. Some tumours progress from urothelial hyperplasia to low-grade non-invasive superficial papillary tumours. More aggressive variants arise either from flat, high-grade carcinoma in situ (CIS) and progress to invasive tumours, or they arise de novo as invasive tumours. Low-grade papillary tumors frequently show a constitutive activation of the receptor tyrosine kinase-Ras pathway, exhibiting activating mutations in the HRAS and fibroblast growth factor receptor 3 (FGFR3) genes. In contrast, CIS and invasive tumors frequently show alterations in the TP53 and RB genes and pathways. Invasion and metastases are promoted by several factors that alter the tumour microenvironment, including the aberrant expression of E-cadherins (E-cad), matrix metalloproteinases (MMPs), angiogenic factors such as vascular endothelial growth factor (VEGF).

MalaCards based summary : Bladder Cancer, also known as bladder carcinoma, is related to bladder urothelial carcinoma and prostate cancer. An important gene associated with Bladder Cancer is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Bladder cancer and MicroRNAs in cancer. The drugs Tamsulosin and Lidocaine have been mentioned in the context of this disorder. Affiliated tissues include urinary bladder, prostate and lymph node, and related phenotype is transitional cell carcinoma of the bladder.

Disease Ontology : 12 An urinary system cancer that results in malignant growth located in the urinary bladder.

MedlinePlus Genetics : 43 Bladder cancer is a disease in which certain cells in the bladder become abnormal and multiply uncontrollably to form a tumor. The bladder is a muscular organ in the lower abdomen that stores urine until it can be removed (excreted) from the body.Bladder cancer may cause blood in the urine, pain during urination, frequent urination, the feeling of needing to urinate without being able to, or lower back pain. Many of these signs and symptoms are nonspecific, which means they may occur in multiple disorders. People who have one or more of these nonspecific health problems often do not have bladder cancer, but have another condition such as an infection.Bladder cancer develops when tumors form in the tissue that lines the bladder. There are several types of bladder cancer, categorized by the type of cell in the tissue that becomes cancerous. The most common type is transitional cell carcinoma (also known as urothelial carcinoma); others include squamous cell carcinoma and adenocarcinoma. If the tumor spreads  (metastasizes) beyond the lining of the bladder into nearby tissues or organs, it is known as invasive bladder cancer.

GARD : 20 Bladder cancer is a form of cancer that occurs due to abnormal and uncontrolled cell growth in the bladder. Signs and symptoms of the condition may include abdominal pain, blood in the urine, fatigue, painful urination, frequent urination, incontinence, and/or weightloss. Most cases of bladder cancer occur sporadically in people with no family history of the condition. Risk factors for the condition include smoking, exposure to certain chemicals, and having chronic bladder infections. Treatment varies based on the severity of the condition and may include surgery, radiation therapy, chemotherapy, and/or biological therapy.

MedlinePlus : 42 The bladder is a hollow organ in your lower abdomen that stores urine. Bladder cancer occurs in the lining of the bladder. It is the sixth most common type of cancer in the United States. Symptoms include Blood in your urine A frequent urge to urinate Pain when you urinate Low back pain Risk factors for developing bladder cancer include smoking and exposure to certain chemicals in the workplace. People with a family history of bladder cancer or who are older, white, or male have a higher risk. Treatments for bladder cancer include surgery, radiation therapy, chemotherapy, and biologic therapy. Biologic therapy boosts your body's own ability to fight cancer. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 73 Bladder cancer: A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas that begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.

Wikipedia : 74 Bladder cancer is any of several types of cancer arising from the tissues of the urinary bladder.... more...

More information from OMIM: 109800

Related Diseases for Bladder Cancer

Diseases in the Bladder Cancer family:

Bladder Carcinoma in Situ

Diseases related to Bladder Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 977)
# Related Disease Score Top Affiliating Genes
1 bladder urothelial carcinoma 32.8 TUG1 PVT1 KRAS HRAS HOTAIR GAS5
2 prostate cancer 32.1 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
3 lung cancer 32.1 ZEB2-AS1 UCA1 TUG1 RB1 PVT1 MIR221
4 renal cell carcinoma, nonpapillary 32.0 ZEB2-AS1 UCA1 TUG1 PVT1 MIR221 MIR21
5 adenocarcinoma 32.0 RB1 KRAS HRAS H19 FGFR3
6 kidney cancer 31.9 PVT1 MIR21 HOTAIR H19 GAS5
7 squamous cell carcinoma 31.8 UCA1 TUG1 RB1 HRAS HOTAIR H19
8 colorectal cancer 31.8 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
9 breast cancer 31.6 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
10 lung cancer susceptibility 3 31.6 TUG1 RB1 MIR21 KRAS HRAS HOTAIR
11 gallbladder cancer 31.6 UCA1 TUG1 MIR143 KRAS HOTAIR H19
12 hepatocellular carcinoma 31.6 ZEB2-AS1 UCA1 TUG1 RB1 PVT1 MIR221
13 b-cell lymphoma 31.6 TUG1 PVT1 MIR21 HOTAIR GAS5
14 melanoma 31.6 UCA1 RB1 PVT1 MIR221 MIR127 KRAS
15 gastric cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
16 cervical cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR21 MIR143
17 ovarian cancer 31.5 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
18 sarcoma 31.4 RB1 KRAS HRAS HOTAIR FGFR3
19 glioblastoma 31.4 TUG1 RB1 MIR221 MIR21 MIR10B HRAS
20 rectum cancer 31.3 MIR21 MIR143 KRAS HRAS
21 non-invasive bladder papillary urothelial neoplasm 31.3 FGFR3 BRINP1
22 myeloma, multiple 31.3 UCA1 TUG1 PVT1 MIR21 KRAS HRAS
23 rhabdomyosarcoma 31.3 RB1 KRAS HRAS H19 FGFR3
24 endometrial cancer 31.2 UCA1 TUG1 RB1 KRAS HRAS HOTAIR
25 esophageal cancer 31.2 UCA1 RB1 PVT1 MIR21 MIR143 MIR10B
26 lynch syndrome 31.2 RB1 KRAS HRAS FGFR3
27 osteogenic sarcoma 31.1 UCA1 TUG1 RB1 PVT1 HOTAIR H19
28 pancreatic ductal adenocarcinoma 31.1 UCA1 PVT1 MIR221 MIR21 MIR143 KRAS
29 lung squamous cell carcinoma 31.1 TUG1 PVT1 KRAS HRAS FGFR3
30 neuroblastoma 31.1 MIR221 MIR21 HRAS HOTAIR H19 GAS5
31 nasopharyngeal carcinoma 31.1 PVT1 MIR21 MIR143 MIR10B HRAS HOTAIR
32 pancreatic cancer 31.0 UCA1 TUG1 RB1 PVT1 MIR221 MIR21
33 thyroid carcinoma 31.0 UCA1 PVT1 HOTAIR H19 GAS5
34 small cell cancer of the lung 31.0 TUG1 RB1 MIR21 HOTAIR
35 appendix adenocarcinoma 31.0 KRAS HRAS
36 leukemia, chronic myeloid 31.0 UCA1 KRAS HRAS HOTAIR H19
37 cholangiocarcinoma 30.9 UCA1 TUG1 MIR21 KRAS H19
38 retinitis pigmentosa 11 30.9 UCA1 TUG1 PVT1 HOTAIR GAS5
39 penile cancer 30.9 RB1 KRAS HRAS
40 gastric adenocarcinoma 30.9 KRAS HRAS HOTAIR H19
41 leukemia, chronic lymphocytic 30.9 MIR221 MIR21 MIR143 MIR10B KRAS HRAS
42 urinary system disease 30.8 MIR221 MIR21 MIR143 MIR10B
43 squamous cell carcinoma, head and neck 30.8 RB1 MIR221 MIR21 MIR143 HRAS HOTAIR
44 glioma 30.8 UCA1 PVT1 MIR221 MIR21 MIR10B HOTAIR
45 oral squamous cell carcinoma 30.8 UCA1 TUG1 MIR221 MIR21 MIR143 HRAS
46 ascending colon cancer 30.8 KRAS HRAS
47 nevus, epidermal 30.7 KRAS HRAS FGFR3
48 lung benign neoplasm 30.7 RB1 KRAS HRAS
49 hematologic cancer 30.7 RB1 PVT1 MIR221 MIR21 MIR143 MIR127
50 acute promyelocytic leukemia 30.7 RB1 PVT1 MIR221 KRAS HRAS

Comorbidity relations with Bladder Cancer via Phenotypic Disease Network (PDN): (show all 17)


Acute Cystitis Acute Kidney Failure
Bladder Neck Obstruction Cystitis
Cystitis Cystica Deficiency Anemia
Hydronephrosis Neutropenia
Paralytic Ileus Prostate Cancer
Prostatic Hypertrophy Radiation Cystitis
Renal Pelvis Carcinoma Ureter, Cancer of
Urethral Benign Neoplasm Urethral Stricture
Urinary Tract Obstruction

Graphical network of the top 20 diseases related to Bladder Cancer:



Diseases related to Bladder Cancer

Symptoms & Phenotypes for Bladder Cancer

Human phenotypes related to Bladder Cancer:

31
# Description HPO Frequency HPO Source Accession
1 transitional cell carcinoma of the bladder 31 HP:0006740

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Mar-2021)
Neoplasia:
bladder cancer
transitional cell bladder carcinoma

Clinical features from OMIM®:

109800 (Updated 05-Mar-2021)

Drugs & Therapeutics for Bladder Cancer

Drugs for Bladder Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 437)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
2
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
3
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
4
Lornoxicam Approved, Investigational Phase 4 70374-39-9 5282204
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
7
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
8
Neostigmine Approved, Vet_approved Phase 4 59-99-4 4456
9
Mepivacaine Approved, Vet_approved Phase 4 96-88-8 4062
10
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
11
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
12
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
13
Sulfamethoxazole Approved Phase 4 723-46-6 5329
14
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
15
Ofloxacin Approved Phase 4 82419-36-1 4583
16
Clindamycin Approved, Vet_approved Phase 4 18323-44-9 29029
17
Trimethoprim Approved, Vet_approved Phase 4 738-70-5 5578
18
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
19
Nitrofurantoin Approved, Vet_approved Phase 4 67-20-9 5353830
20
Remifentanil Approved Phase 4 132875-61-7 60815
21
Cisatracurium Approved Phase 4 96946-41-7 62887
22
Sufentanil Approved, Investigational Phase 4 56030-54-7 41693
23
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
24 Adrenergic alpha-1 Receptor Antagonists Phase 4
25 Adrenergic alpha-Antagonists Phase 4
26 Antirheumatic Agents Phase 4
27 Sodium Channel Blockers Phase 4
28 Cephalosporins Phase 4
29 Diuretics, Potassium Sparing Phase 4
30 GABA Modulators Phase 4
31 Omega 3 Fatty Acid Phase 4
32 Solifenacin succinate Phase 4 242478-38-2
33 Cholinergic Antagonists Phase 4
34 Cholinergic Agents Phase 4
35 Central Nervous System Stimulants Phase 4
36 Nicotinic Agonists Phase 4
37 Anticonvulsants Phase 4
38 Psychotropic Drugs Phase 4
39 Dopamine Agents Phase 4
40 Dopamine Uptake Inhibitors Phase 4
41 Antidepressive Agents Phase 4
42 Neuromuscular Blocking Agents Phase 4
43 Muscarinic Antagonists Phase 4
44 Neuromuscular Nondepolarizing Agents Phase 4
45
Glycopyrrolate Phase 4 596-51-0 3494
46 Cholinesterase Inhibitors Phase 4
47 Bromides Phase 4
48 Hypnotics and Sedatives Phase 4
49 Anesthetics, Intravenous Phase 4
50 Anesthetics, General Phase 4

Interventional clinical trials:

(show top 50) (show all 1061)
# Name Status NCT ID Phase Drugs
1 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Unknown status NCT02443844 Phase 4 Tamsulosin
2 Ultrasound-Guided Obturator Nerve Block for Transurethral Procedures - Interadductor Approach Unknown status NCT02696733 Phase 4 lidocaine 2%;0.9% Natrium Chloratum with a 2nd generation cephalosporin
3 The Assessment of Postoperative Cognitive Dysfunction After Transurethral Resection of Bladder Tumor Under Spinal Anesthesia Unknown status NCT03029676 Phase 4 benzodiazepines;opioid
4 The Effects of Sequential Mitomycin and Bacillus Calmette-Guérin Treatment Versus Bacillus Calmette-Guérin Monotherapy in Patients With High Risk Non-Muscle Invasive Bladder Cancer Unknown status NCT03790384 Phase 4 Mitomycin
5 Chemoradiotherapy for Recurrent T1G3 Bladder Cancer After BCG Failure Unknown status NCT03274284 Phase 4
6 Solifenacin vs Levofloxacin vs Lornoxicam for Management of Intravesical Instillation of Bacillus Calmette-Guerin (BCG) Side Effects A Single Blinded Randomised Controlled Study Unknown status NCT03038321 Phase 4 sofenacin;Tavanic;Xefo
7 Influence of Immune Nutrition Diet on 90-Day Outcomes in Patients Undergoing Radical Cystectomy and Bladder Substitutions: A Randomized Controlled Trial Unknown status NCT03147586 Phase 4 Bio-tech and omega-3 plus;placebo
8 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
9 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Unknown status NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
10 In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? Completed NCT03174912 Phase 4
11 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
12 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
13 The Value of Immediate Post-operative Intravesical Epirubicin Instillation in Intermediate and High Risk Non Muscle Invasive Bladder Cancer (NMIBC): A Randomized Controlled Trial Completed NCT02214602 Phase 4 Epirubicin
14 A Phase IV Investigation of Sugammadex in Outpatient Urological Procedures Completed NCT03138967 Phase 4 Rocuronium;Sugammadex;Neostigmine;Glycopyrrolate
15 Comparison of Obturator Nerve Blockade and Neuromuscular Blockade for the Prevention of Adductor Spasm in Patients Undergoing Transurethral Resection of Bladder Tumors. Completed NCT03063255 Phase 4 Obturator block;Neuromuscular block
16 Effect of TachoSil® on Incidence of Symptomatic and Radiographic Lymphoceles After Extended Pelvic Lymph Node Dissection in Prostate and Bladder Cancer. Completed NCT02001857 Phase 4 1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.
17 The Effect of Neuromuscular Blockade During Transurethral Resection of Bladder Cancer on Surgical Condition and Recovery Profiles : A Prospective, Randomized and Controlled Trial Completed NCT03039543 Phase 4 Rocuronium;Sugammadex
18 Does Prophylactic Antibiotic Decrease the Rate of Urinary Tract Infection After Robot Assisted Radical Cystectomy Recruiting NCT04502095 Phase 4 Clindamycin;Ertapenem;Levofloxacin;Nitrofurantoin;Trimethoprim-Sulfamethoxazole
19 Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial Recruiting NCT04532606 Phase 4 Remimazolam;Propofol
20 Neoadjuvant Short-term Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in NMIBC Active, not recruiting NCT03348969 Phase 4 Mitomycin c
21 Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study Not yet recruiting NCT03221062 Phase 4
22 Must Aspirin be Discontinued Prior to TURBT: a Prospective, Randomized, Non-inferiority Trial Comparing Peri-operative Aspirin Continuation Versus Discontinuation. Terminated NCT02350543 Phase 4 Aspirin
23 Recurrence of Bladder Cancer After Transurethral Resection With Hexvix Withdrawn NCT00785694 Phase 4 hexaminolevulinate
24 A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT) Unknown status NCT02695771 Phase 3 Mitomycin C;Gemcitabine
25 Treatment of Ta Bladder Cancer in High Risk of Recurrence - Fluorescence Cystoscopy With Optimized Adjuvant Mitomycin-C (FinnBladder 9) Unknown status NCT01675219 Phase 3 optimized MMC;single immediate chemotherapy instillation
26 Adjuvant vs. Progression-Triggered Treatment With Gemcitabine After Radical Cystectomy for Locally Advanced Transitional Cell Carcinoma of the Bladder in Patients Not Suitable for Cisplatin-Based Chemotherapy - A Phase 3 Study Unknown status NCT00146276 Phase 3 gemcitabine
27 Phase III Randomized Study of a Single Adjunctive Instillation of Intravesical AD 32 (N-Trifluoroacetyladriamycin-14-valerate) Versus No Adjunctive Therapy Immediately Following Transurethral Resection in Patients With Multiple Superficial (Ta/T1) Bladder Tumors Unknown status NCT00003725 Phase 3 valrubicin
28 Using Biploar Technology for Transurethral Resection of Bladder Tumor - a Randomized Controlled Trial Unknown status NCT01581723 Phase 3
29 Determining the Specificity and Sensitivity of the BladderLight™ Assay as a Diagnostic and Risk Stratification Tool for Bladder Cancer Unknown status NCT03427034 Phase 2, Phase 3
30 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) Unknown status NCT00553124 Phase 3 selenium;vitamin E
31 HYMN: A Randomized Controlled Phase III Trial Comparing Hyperthermia Plus Mitomycin to a Second Course of Bacillus Calmette-Guerin or Standard Therapy in Patients With Recurrence of Non-Muscle Invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guerin Therapy Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
32 Phase III Study Of Adjuvant Cisplatin-Gemcitabine Vs. Observation After Radical Cystectomy In High-Risk Bladder Cancer Unknown status NCT00054626 Phase 3 cisplatin;gemcitabine hydrochloride
33 Adjuvant Chemotherapy Following Radical Cystectomy to Treat Locally Advanced Bladder Cancer Unknown status NCT02074189 Phase 3 Gemcitabine, Cisplatin
34 Bladder Cancer Prognosis Programme (Incorporating SELENIB Trial) [TREATMENT] Unknown status NCT00553345 Phase 3 selenium;vitamin E
35 Study of the Efficacy of Maintenance Therapy by UFT or BCG for Superficial Bladder Cancer Against Recurrence in Urological Oncology Council of Northern Tokyo: EMBARK Study Unknown status NCT01082510 Phase 3 Bacille Calmette-Guerin;uracil-tegafur
36 A Phase II/III, Randomised, Two-Arm, Comparison of Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With HER1 and/or HER2 Overexpressing Locally Advanced or Metastatic Bladder Cancer [LaMB] Unknown status NCT00949455 Phase 2, Phase 3 lapatinib ditosylate
37 The Impact of Early Feeding After Radical Cystectomy for Bladder Cancer Unknown status NCT01489800 Phase 3
38 Adding Mitomycin C to Bacillus of Calmette-Guerin (BCG) as Adjuvant Intravesical Therapy for High-risk, Non-Muscle-invasive Bladder Cancer: a Randomised Phase 3 Trial Unknown status NCT02948543 Phase 3 Mitomycin C (MMC)
39 The Efficacy of Distilled Water vs Mitomycin C as a Single Dose Immediate Instillation After Transurethral Resection of Intermediate Risk, Recurrent Superficial Bladder Cancer Unknown status NCT00816075 Phase 2, Phase 3 distilled water
40 A Study of Comparing Effects of Thulium Laser en Bloc Resection and Electrical Transurethral Resection of the Non-muscle Invasive Bladder Cancer Unknown status NCT02951078 Phase 3
41 Randomized Double-Blind Controlled Phase III Trial of Hyperbaric Oxygen Therapy in Patients Suffering Long-Term Adverse Effects of Radiotherapy for Pelvic Cancer (HOT II) Unknown status NCT01087268 Phase 3
42 Efficacy of Diclofenac Suppositories in Prevention of Immediate Side Effects of BCG Bladder Irrigations. A Double Blind Placebo Controlled Randomized Study Unknown status NCT01542567 Phase 3 Abitren;Placebo
43 A Prospective Randomized Phase III Trial of Maintenance Pemetrexed Versus Observation in Patients With Recurrent or Metastatic Urothelial Carcinoma Who Completed First Line Platinum-based Chemotherapy Without Disease Progression Unknown status NCT03193788 Phase 3 pemetrexed;Folic Acid;Vitamin B12 Injection;Dexamethasone
44 A Multi-centre Randomised Controlled Double-blinded Trial of BCG and Interferon Alpha in High Risk Superficial Bladder Cancer Completed NCT00330707 Phase 2, Phase 3 Bacillus Calmette Guerin and interferon alpha
45 An Open, Comparative, Within Patient, Controlled Phase III, Multicenter Study Of HEXVIX Fluorescence Cystoscopy And White Light Cystoscopy In the Detection Of Carcinoma In Situ In Patients With Bladder Cancer Completed NCT00052637 Phase 3 hexaminolevulinate
46 Randomized Study of LAROTAXEL + Cisplatin (LC) vs. Gemcitabine + Cisplatin (GC) in the First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer Completed NCT00625664 Phase 3 larotaxel (XRP9881);gemcitabine;cisplatin
47 A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single-Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-612) Completed NCT00598806 Phase 3 Apaziquone;Placebo
48 A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Phase 3 Trial of Single Dose Intravesical Apaziquone (EOquin®) as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing Transurethral Resection for Noninvasive Bladder Cancer (Protocol SPI-611) Completed NCT00461591 Phase 3 Apaziquone;Placebo
49 A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papollary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ Completed NCT00003779 Phase 3
50 A Randomised Trial of Radical Chemo/Radiotherapy vs Radiotherapy Alone in the Definitive Management of Localised Muscle Invasive TCC of the Urinary Bladder Completed NCT00330499 Phase 3 Cisplatin

Search NIH Clinical Center for Bladder Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


BCG Vaccine
Carboplatin
Cisplatin
CISPLATIN PWDR
doxorubicin hydrochloride liposome
Etoposide
etoposide phosphate
pembrolizumab
Thiotepa

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Bladder Cancer cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Bladder Cancer:
Neo-Urinary Conduit, smooth muscle cell 3D culture for bladder diseases
Embryonic/Adult Cultured Cells Related to Bladder Cancer:
Neo-Urinary Conduit PMIDs: 22136657

Cochrane evidence based reviews: urinary bladder neoplasms

Genetic Tests for Bladder Cancer

Genetic tests related to Bladder Cancer:

# Genetic test Affiliating Genes
1 Urinary Bladder Cancer 29 FGFR3 HRAS KRAS RB1
2 Bladder Carcinoma 29
3 Bladder Neoplasm 29
4 Bladder Cancer 29

Anatomical Context for Bladder Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bladder Cancer:

19
Urinary Bladder

MalaCards organs/tissues related to Bladder Cancer:

40
Prostate, Lymph Node, Lung, Kidney, Endothelial, Neutrophil, Breast

Publications for Bladder Cancer

Articles related to Bladder Cancer:

(show top 50) (show all 35011)
# Title Authors PMID Year
1
Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. 57 6
10471491 1999
2
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. 57 61
25428503 2014
3
Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. 57 61
24121792 2013
4
Frequent truncating mutations of STAG2 in bladder cancer. 61 57
24121789 2013
5
Recurrent inactivation of STAG2 in bladder cancer is not associated with aneuploidy. 57 61
24121791 2013
6
Genome sequencing identifies a basis for everolimus sensitivity. 61 57
22923433 2012
7
Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. 57 61
21822268 2011
8
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. 61 57
20591884 2010
9
A sequence variant at 4p16.3 confers susceptibility to urinary bladder cancer. 57 61
20348956 2010
10
Sequence variant on 8q24 confers susceptibility to urinary bladder cancer. 57 61
18794855 2008
11
Mitochondrial cytochrome B gene mutation promotes tumor growth in bladder cancer. 61 57
18245469 2008
12
Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. 61 57
16465622 2006
13
Identifying distinct classes of bladder carcinoma using microarrays. 61 57
12469123 2003
14
Cytogenetics and molecular genetics of bladder cancer: a personal view. 61 57
12407698 2002
15
Familial transitional cell carcinoma. 57 61
8709350 1996
16
Slow N-acetylation genotype is a susceptibility factor in occupational and smoking related bladder cancer. 61 57
7757072 1995
17
Definition of two regions of deletion on chromosome 9 in carcinoma of the bladder. 57 61
8208555 1994
18
Loss of heterozygosity on chromosome 11p13 in primary bladder carcinoma. 61 57
8100210 1993
19
Clonal origin of bladder cancer. 61 57
1445507 1992
20
Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. 6 54
2181449 1990
21
Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. 57 61
2293558 1990
22
Loss of genes on the short arm of chromosome 11 in bladder cancer. 6 61
2999610 1985
23
Oncogene from human EJ bladder carcinoma is located on the short arm of chromosome 11. 57 61
6297001 1983
24
Activation of the T24 bladder carcinoma transforming gene is linked to a single amino acid change. 6 61
7177195 1982
25
Isolation and preliminary characterization of a human transforming gene from T24 bladder carcinoma cells. 61 57
7063039 1982
26
Familial aggregation of urothelial carcinoma. 61 57
7053069 1981
27
Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. 61 57
7207618 1981
28
Transforming activity of human tumor DNAs. 57 61
6940134 1981
29
Familial factors in bladder carcinoma. 57 61
480484 1979
30
Abnormal tryptophan metabolism in a family with a history of bladder cancer. 57 61
994212 1976
31
lncRNA TINCR SNPs and Expression Levels Are Associated with Bladder Cancer Susceptibility. 42 61
33372851 2021
32
The Tumor Microenvironment and Immunotherapy in Prostate and Bladder Cancer. 61 42
33446323 2020
33
Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. 57
25722414 2015
34
Keratinocytic epidermal nevi are associated with mosaic RAS mutations. 6
22499344 2012
35
MicroRNA-221 silencing predisposed human bladder cancer cells to undergo apoptosis induced by TRAIL. 61 47
19767219 2010
36
A microRNA expression ratio defining the invasive phenotype in bladder tumors. 61 47
18799331 2010
37
Distinct microRNA alterations characterize high- and low-grade bladder cancer. 47 61
19843843 2009
38
MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. 54 47
19593777 2009
39
Identification of novel microRNA targets based on microRNA signatures in bladder cancer. 47 61
19378336 2009
40
Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. 47 61
19487295 2009
41
MicroRNA-143 as a tumor suppressor for bladder cancer. 61 47
19157460 2009
42
Acanthosis nigricans in a child with mild osteochondrodysplasia and K650Q mutation in the FGFR3 gene. 6
18000903 2007
43
Micro-RNA profiling in kidney and bladder cancers. 61 47
17826655 2007
44
Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation. 6
17412879 2007
45
Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia. 6
16912704 2006
46
Germline mutations in HRAS proto-oncogene cause Costello syndrome. 6
16170316 2005
47
Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans. 6
15772091 2005
48
Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma. 6
11314002 2001
49
Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype. 6
11055896 2000
50
Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. 57
10720328 2000

Variations for Bladder Cancer

ClinVar genetic disease variations for Bladder Cancer:

6 (show top 50) (show all 88)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MRE11 NM_005590.4(MRE11):c.*1359T>C SNV other 60639 rs397509348 11:94151932-94151932 11:94418766-94418766
2 MRE11 NM_005590.4(MRE11):c.*2731G>A SNV other 60640 rs397509349 11:94150560-94150560 11:94417394-94417394
3 MRE11 NM_005590.4(MRE11):c.*631C>T SNV other 60642 rs397509347 11:94152660-94152660 11:94419494-94419494
4 MRE11 NM_005590.4(MRE11):c.-105-326A>T SNV other 60643 rs183829476 11:94226398-94226398 11:94493232-94493232
5 MRE11 NM_005590.4(MRE11):c.-105-387C>T SNV other 60644 rs397509350 11:94226459-94226459 11:94493293-94493293
6 MRE11 NM_005590.4(MRE11):c.1098+1177G>A SNV other 60645 rs369782842 11:94199802-94199802 11:94466636-94466636
7 MRE11 NM_005590.4(MRE11):c.1098+1408A>G SNV other 60646 rs200367125 11:94199571-94199571 11:94466405-94466405
8 MRE11 NM_005590.4(MRE11):c.1098+1620T>C SNV other 60647 rs397509352 11:94199359-94199359 11:94466193-94466193
9 MRE11 NM_005590.4(MRE11):c.1098+614C>T SNV other 60648 rs140067184 11:94200365-94200365 11:94467199-94467199
10 MRE11 NM_005590.4(MRE11):c.1225+40T>C SNV other 60650 rs192979170 11:94197239-94197239 11:94464073-94464073
11 MRE11 NM_005590.4(MRE11):c.1225+572A>T SNV other 60651 rs397509353 11:94196707-94196707 11:94463541-94463541
12 MRE11 NM_005590.4(MRE11):c.1225+577A>C SNV other 60652 rs397509354 11:94196702-94196702 11:94463536-94463536
13 MRE11 NM_005590.4(MRE11):c.1225+605T>C SNV other 60653 rs397509355 11:94196674-94196674 11:94463508-94463508
14 MRE11 NM_005590.4(MRE11):c.1225+804T>C SNV other 60654 rs397509356 11:94196475-94196475 11:94463309-94463309
15 MRE11 NM_005590.4(MRE11):c.1327-461A>C SNV other 60655 rs185485357 11:94193208-94193208 11:94460042-94460042
16 MRE11 NM_005590.4(MRE11):c.1783+561G>A SNV other 60656 rs397509357 11:94179824-94179824 11:94446658-94446658
17 MRE11 NM_005590.4(MRE11):c.1783+888A>G SNV other 60657 rs397509358 11:94179497-94179497 11:94446331-94446331
18 MRE11 NM_005590.4(MRE11):c.20+821G>A SNV other 60658 rs397509351 11:94225127-94225127 11:94491961-94491961
19 MRE11 NM_005590.4(MRE11):c.314+99A>G SNV other 60659 rs143677623 11:94218991-94218991 11:94485825-94485825
20 MRE11 NM_005590.4(MRE11):c.545-297G>T SNV other 60660 rs118024137 11:94209866-94209866 11:94476700-94476700
21 MRE11 NM_005590.4(MRE11):c.1563+281G>A SNV other 60672 rs397509429 11:94189161-94189161 11:94455995-94455995
22 MRE11 NM_005590.4(MRE11):c.1202A>G (p.His401Arg) SNV other 60649 rs146779325 11:94197302-94197302 11:94464136-94464136
23 MRE11 NM_005590.4(MRE11):c.*570A>C SNV other 60641 rs397509346 11:94152721-94152721 11:94419555-94419555
24 KRAS NM_004985.5(KRAS):c.34G>C (p.Gly12Arg) SNV Pathogenic 12579 rs121913530 12:25398285-25398285 12:25245351-25245351
25 HRAS NM_005343.4(HRAS):c.35G>T (p.Gly12Val) SNV Pathogenic 12600 rs104894230 11:534288-534288 11:534288-534288
26 RB1 NM_000321.2(RB1):c.2107-2A>G SNV Pathogenic 13077 rs1593538130 13:49037865-49037865 13:48463729-48463729
27 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
28 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
29 FGFR3 NM_000142.5(FGFR3):c.1949A>C (p.Lys650Thr) SNV Pathogenic 65855 rs121913105 4:1807890-1807890 4:1806163-1806163
30 HRAS NM_005343.4(HRAS):c.37G>T (p.Gly13Cys) SNV Pathogenic 12606 rs104894228 11:534286-534286 11:534286-534286
31 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala) SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
32 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
33 FGFR3 NM_000142.5(FGFR3):c.742C>T (p.Arg248Cys) SNV Pathogenic 16332 rs121913482 4:1803564-1803564 4:1801837-1801837
34 FGFR3 NM_000142.5(FGFR3):c.749C>G (p.Pro250Arg) SNV Pathogenic 16340 rs4647924 4:1803571-1803571 4:1801844-1801844
35 FGFR3 NM_000142.5(FGFR3):c.1138G>A SNV Pathogenic 16327 rs28931614 4:1806119-1806119 4:1804392-1804392
36 FGFR3 NM_000142.5(FGFR3):c.1620C>G (p.Asn540Lys) SNV Pathogenic 16338 rs28933068 4:1807371-1807371 4:1805644-1805644
37 KRAS NM_004985.5(KRAS):c.458A>T (p.Asp153Val) SNV Pathogenic 12587 rs104894360 12:25362838-25362838 12:25209904-25209904
38 RB1 NM_000321.3(RB1):c.1215+1G>A SNV Pathogenic 126832 rs587776783 13:48947629-48947629 13:48373493-48373493
39 RB1 NM_000321.3(RB1):c.1981C>T SNV Pathogenic 13087 rs137853294 13:49033844-49033844 13:48459708-48459708
40 FGFR3 NM_000142.5(FGFR3):c.1948A>C (p.Lys650Gln) SNV Pathogenic 16348 rs78311289 4:1807889-1807889 4:1806162-1806162
41 FGFR3 NM_000142.5(FGFR3):c.1108G>T (p.Gly370Cys) SNV Likely pathogenic 16359 rs121913479 4:1806089-1806089 4:1804362-1804362
42 FGFR3 NM_001163213.1(FGFR3):c.746C>G (p.Ser249Cys) SNV Likely pathogenic 16339 rs121913483 4:1803568-1803568 4:1801841-1801841
43 FGFR3 NM_000142.5(FGFR3):c.1111A>T (p.Ser371Cys) SNV Likely pathogenic 16333 rs121913484 4:1806092-1806092 4:1804365-1804365
44 FGFR3 NM_000142.5(FGFR3):c.2089G>T (p.Gly697Cys) SNV Likely pathogenic 376248 rs121913480 4:1808331-1808331 4:1806604-1806604
45 FGFR3 NM_000142.5(FGFR3):c.1948A>C (p.Lys650Gln) SNV Likely pathogenic 16348 rs78311289 4:1807889-1807889 4:1806162-1806162
46 FGFR3 NM_000142.5(FGFR3):c.1118A>G (p.Tyr373Cys) SNV Likely pathogenic 16342 rs121913485 4:1806099-1806099 4:1804372-1804372
47 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys) SNV Likely pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
48 FGFR3 NM_000142.5(FGFR3):c.200G>A (p.Gly67Asp) SNV Uncertain significance 546226 rs369232922 4:1801071-1801071 4:1799344-1799344
49 FGFR3 NM_000142.5(FGFR3):c.1993G>T (p.Ala665Ser) SNV Uncertain significance 465350 rs764892330 4:1808017-1808017 4:1806290-1806290
50 FGFR3 NM_000142.5(FGFR3):c.2153A>G (p.Asn718Ser) SNV Uncertain significance 521225 rs139773438 4:1808395-1808395 4:1806668-1806668

UniProtKB/Swiss-Prot genetic disease variations for Bladder Cancer:

73
# Symbol AA change Variation ID SNP ID
1 FGFR3 p.Arg248Cys VAR_004148 rs121913482
2 FGFR3 p.Ser249Cys VAR_004149 rs121913483
3 FGFR3 p.Gly370Cys VAR_004151 rs121913479
4 FGFR3 p.Lys650Glu VAR_004160 rs78311289
5 FGFR3 p.Lys650Gln VAR_018390 rs78311289

Cosmic variations for Bladder Cancer:

9 (show top 50) (show all 23555)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM88263080 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.946G>C p.E316Q 23:15822739-15822739 4
2 COSM88263088 ZRSR2 urinary tract,bladder,carcinoma,transitional cell carcinoma c.965G>A p.R322K 23:15822758-15822758 4
3 COSM84510685 ZNF276 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.*420C>T p.? 16:89738666-89738666 4
4 COSM102043690 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8060C>T p.S2687L 16:72787474-72787474 4
5 COSM87276544 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4937C>T p.S1646F 16:72797745-72797745 4
6 COSM102034006 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.7070C>T p.T2357M 16:72788464-72788464 4
7 COSM149314765 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9829C>T p.P3277S 16:72788447-72788447 4
8 COSM87290232 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9829C>T p.P3277S 16:72788447-72788447 4
9 COSM102035771 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-6747G>C p.? 16:72957712-72957712 4
10 COSM102022922 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2903T>A p.I968N 16:72797037-72797037 4
11 COSM87284313 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.6608G>A p.R2203H 16:72796074-72796074 4
12 COSM102041865 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-8627C>T p.? 16:72959592-72959592 4
13 COSM102042377 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5648G>T p.R1883I 16:72794292-72794292 4
14 COSM102026671 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5057C>G p.S1686* 16:72794883-72794883 4
15 COSM149282136 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8029G>A p.E2677K 16:72794653-72794653 4
16 COSM87286129 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2249A>G p.H750R 16:72957897-72957897 4
17 COSM102042654 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.-23-9030G>A p.? 16:72959995-72959995 4
18 COSM87296773 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.11065A>T p.K3689* 16:72787211-72787211 4
19 COSM149332078 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.11065A>T p.K3689* 16:72787211-72787211 4
20 COSM149268190 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5645T>A p.I1882N 16:72797037-72797037 4
21 COSM102034185 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5969A>G p.K1990R 16:72793971-72793971 4
22 COSM149297301 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9812C>T p.T3271M 16:72788464-72788464 4
23 COSM102042394 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2674G>C p.E892Q 16:72797266-72797266 4
24 COSM149318900 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.5416G>C p.E1806Q 16:72797266-72797266 4
25 COSM149321603 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9964C>T p.Q3322* 16:72788312-72788312 4
26 COSM87291296 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.554C>T p.S185L 16:72959592-72959592 4
27 COSM87293009 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.10802C>T p.S3601L 16:72787474-72787474 4
28 COSM102023535 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.1853A>G p.N618S 16:72798087-72798087 4
29 COSM102047988 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-8556G>A p.? 16:72959521-72959521 4
30 COSM149317827 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.554C>T p.S185L 16:72959592-72959592 4
31 COSM102036900 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.2138C>T p.A713V 16:72797802-72797802 4
32 COSM87286411 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.5886G>T p.E1962D 16:72796796-72796796 4
33 COSM87285294 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2434G>C p.E812Q 16:72957712-72957712 4
34 COSM87296470 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.883C>T p.R295C 16:72959263-72959263 4
35 COSM102025882 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.-23-6951C>T p.? 16:72957916-72957916 4
36 COSM149265910 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8849G>A p.R2950H 16:72793833-72793833 4
37 COSM149262739 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8376G>A p.M2792I 16:72794306-72794306 4
38 COSM87273255 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.8849G>A p.R2950H 16:72793833-72793833 4
39 COSM87280212 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.2458C>T p.R820C 16:72957688-72957688 4
40 COSM149304877 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.4880C>T p.A1627V 16:72797802-72797802 4
41 COSM149297628 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8711A>G p.K2904R 16:72793971-72793971 4
42 COSM87291784 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7576C>T p.Q2526* 16:72795106-72795106 4
43 COSM149294302 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.9127A>G p.I3043V 16:72793555-72793555 4
44 COSM87271951 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.8376G>A p.M2792I 16:72794306-72794306 4
45 COSM102047690 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.-23-8298C>T p.? 16:72959263-72959263 4
46 COSM149262746 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.808G>A p.D270N 16:72959338-72959338 4
47 COSM87274117 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.308G>A p.R103H 16:72959838-72959838 4
48 COSM102042385 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.4834C>T p.Q1612* 16:72795106-72795106 4
49 COSM87283980 ZFHX3 urinary tract,upper urinary tract,carcinoma,transitional cell carcinoma c.9812C>T p.T3271M 16:72788464-72788464 4
50 COSM149318895 ZFHX3 urinary tract,bladder,carcinoma,transitional cell carcinoma c.7576C>T p.Q2526* 16:72795106-72795106 4

Copy number variations for Bladder Cancer from CNVD:

7 (show top 50) (show all 98)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 36534 1 77068898 77170790 Loss Bladder cancer
2 51778 11 130615965 132678521 Loss Bladder cancer
3 53648 11 31517796 32050223 Loss Bladder cancer
4 58531 11 68323054 69297218 Gain Bladder cancer
5 80757 13 97270228 100084626 Gain Bladder cancer
6 81341 14 101619009 102408085 Loss Bladder cancer
7 83177 14 19364851 19446107 Loss Bladder cancer
8 87829 14 77750645 79747731 Loss Bladder cancer
9 89915 15 19427350 19427409 Loss Bladder cancer
10 96847 15 95052889 95403459 Loss Bladder cancer
11 97491 16 10647794 11795463 Gain Bladder cancer
12 107647 17 1649595 1725887 Loss Bladder cancer
13 109050 17 24000000 38100000 Gain Bladder cancer
14 109225 17 24641926 27576519 Gain Bladder cancer
15 118108 17 7571719 7590863 Loss TP53 Bladder cancer
16 121742 18 467310 796252 Gain Bladder cancer
17 122814 18 61643142 67432063 Loss Bladder cancer
18 126424 19 18749534 19294814 Gain Bladder cancer
19 127148 19 278073 12616127 Gain Bladder cancer
20 135679 2 11956730 12796508 Gain Bladder cancer
21 135959 2 123437325 126399586 Loss Bladder cancer
22 138231 2 159948195 160120757 Loss Bladder cancer
23 141850 2 217249378 242464793 Loss Bladder cancer
24 147190 2 60966923 61033726 Loss Bladder cancer
25 147284 2 62081310 62298660 Loss Bladder cancer
26 148163 2 74469 50579433 Loss Bladder cancer
27 150974 20 157771 456225 Gain Bladder cancer
28 151125 20 17870221 18440898 Gain Bladder cancer
29 151502 20 22093371 26036562 Gain Bladder cancer
30 152003 20 28081598 47163674 Gain Bladder cancer
31 154726 20 48033501 54958791 Gain Bladder cancer
32 156571 20 61727753 62175139 Gain Bladder cancer
33 158507 21 33581851 34132794 Gain Bladder cancer
34 160744 22 16259597 16597551 Loss Bladder cancer
35 164078 22 34482413 35495073 Gain Bladder cancer
36 170412 3 153906953 155170944 Gain Bladder cancer
37 170822 3 159876217 162162404 Gain Bladder cancer
38 171019 3 162425422 164314793 Gain Bladder cancer
39 176797 3 50653920 52539982 Loss Bladder cancer
40 179967 4 1 4500000 Loss Bladder cancer
41 186746 4 38697312 42182524 Loss Bladder cancer
42 193888 5 134523261 135051953 Loss Bladder cancer
43 200115 5 50094582 74360979 Loss Bladder cancer
44 202946 5 90316808 90788310 Loss Bladder cancer
45 203715 6 1 61000000 Gain Bladder cancer
46 204149 6 107127877 107503845 Loss Bladder cancer
47 204292 6 108783383 109034288 Loss Bladder cancer
48 204477 6 11110371 17397320 Gain Bladder cancer
49 205260 6 123251233 125408147 Loss Bladder cancer
50 207124 6 15200000 25200000 Amplification Bladder cancer

Expression for Bladder Cancer

Search GEO for disease gene expression data for Bladder Cancer.

Pathways for Bladder Cancer

Pathways related to Bladder Cancer according to KEGG:

36
# Name Kegg Source Accession
1 Bladder cancer hsa05219
2 MicroRNAs in cancer hsa05206

GO Terms for Bladder Cancer

Biological processes related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 gene silencing by miRNA GO:0035195 9.73 MIR221 MIR21 MIR143 MIR127 MIR10B H19
2 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.71 MIR221 MIR21 HRAS FGFR3
3 miRNA mediated inhibition of translation GO:0035278 9.63 MIR221 MIR21 MIR10B
4 Ras protein signal transduction GO:0007265 9.61 RB1 KRAS HRAS
5 response to isolation stress GO:0035900 9.37 KRAS HRAS
6 negative regulation of interleukin-21 production GO:0032705 9.32 MIR221 MIR21
7 negative regulation of superoxide dismutase activity GO:1901670 9.16 MIR21 H19
8 positive regulation of vascular associated smooth muscle cell migration GO:1904754 9.13 MIR221 MIR21 MIR143
9 positive regulation of protein kinase B signaling GO:0051897 9.02 MIR221 MIR21 MIR143 H19 FGFR3

Molecular functions related to Bladder Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR221 MIR21 MIR143 MIR10B

Sources for Bladder Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....